Roche Venture Fund
Status
ACTIVE
Global HQ
Basel, Switzerland
Countries of investment
- USA
- Switzerland
Investment stages
- Seed
Industries
- FoodTech
- Agtech
- Consumer Services
About
Roche Venture Fund is an integral part of Roche, a global leader in pharmaceuticals and diagnostics committed to transforming patient care through groundbreaking therapies and diagnostic solutions. By investing in innovative startups and emerging technologies, Roche Venture Fund accelerates the development of personalized healthcare, particularly in areas such as oncology, immunology, and infectious diseases. Leveraging Roche's extensive expertise and resources, the fund aims to foster advancements that address unmet medical needs while enhancing overall patient outcomes. Through strategic partnerships, Roche Venture Fund cultivates innovation that aligns with Roche's mission to improve lives worldwide.
Roche Venture Fund is an integral part of Roche, a global leader in pharmaceuticals and diagnostics committed to transforming patient care through groundbreaking therapies and diagnostic solutions. By investing in innovative startups and emerging technologies, Roche Venture Fund accelerates the development of personalized healthcare, particularly in areas such as oncology, immunology, and infectious diseases. Leveraging Roche's extensive expertise and resources, the fund aims to foster advancements that address unmet medical needs while enhancing overall patient outcomes. Through strategic partnerships, Roche Venture Fund cultivates innovation that aligns with Roche's mission to improve lives worldwide.
Investment Thesis
The Roche Venture Fund invests to develop commercially successful innovative life science companies.
Manager's Experience
Bringing extensive experience in healthcare and biotechnology investments, the fund manager has executed over 50 deals, emphasizing early-stage opportunities in Europe and North America. With a strategic focus on operator-first approaches, they have successfully facilitated notable exits, including several high-profile acquisitions. Their investment style is characterized by a data-driven methodology that identifies emerging trends within the life sciences sector. This expertise enables them to build a robust portfolio that aligns with transformative innovations in medical technology.
Team
喔勦父喔撪腑喔｀笂喔?Roche corporate affairs and commercial services
Zollinger Barbara
Zoe Davis
Zena Risheg
Zane Degro
Yvonne Kohl
Yvonne Kienast
Yvonne Tan
Yvonne
Yvette Kueh